PAR23 SURVEY OF GLOBAL FIBROMYALGIA MANAGEMENT BY FRENCH GENERAL PRACTITIONERS  by Thomas, E et al.
667Abstracts
PAR20
PEOPLES PREFERENCES FOR WHO SHOULD GET THE NEXT
JOINT REPLACEMENT
Davies LM, Payne K, Fargher EA
University of Manchester, Manchester, UK
OBJECTIVES: The objectives were to identify and quantify 
the value of preferences for characteristics that should inﬂuence
prioritisation of patients for total joint replacement (TJR).
METHODS: Interviews, a ranking study and literature review
were used to identify the attributes that should inﬂuence TJR pri-
oritisation decisions for people with equal need and expected
outcomes. A discrete choice survey was designed and piloted to
value preferences for key attributes. Three attributes with two
levels (comorbidity; patient provides necessary care for another
person; patients tries to follow doctors instructions to maintain
health and weight) and two attributes with four levels (cost to
the health service; age) were identiﬁed as important characteris-
tics. A fractional factorial design was used, giving 16 patient 
proﬁles and 8 pair-wise choices. For each pair-wise choice,
respondents chose whether patient A or B should be prioritised
for the next available TJR or wait 12 months. Dominance and
consistency tests were included. Each attribute was also ranked
in order of preference. Respondents included patients waiting for
or had a TJR and the general public. RESULTS: There were 80
respondents. The average age was 64 years, 63% were female,
88% were patients, 66% lived with others at home and 53%
were married. In the ranking exercise willingness to follow
doctors instructions was the most preferred characteristic (n =
36, 45%) and cost the least preferred (n = 42, 53%). The analy-
sis indicated that the coefﬁcients for all characteristics except
comorbidity (p = 0.07) were statistically signiﬁcant (p < 0.01).
Overall, people appeared to prefer patients who were willing to
follow doctors instructions, provide necessary care for another
person and were younger to be treated ﬁrst. CONCLUSIONS:
Respondents were willing to choose between patients proﬁles to
prioritise who should receive the next TJR. Important attributes
in the choice were willingness to follow doctors instructions and
whether the patient cared for another.
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CROSS-SURVEY OF RHEUMATOLOGISTS AND GP
AWARENESS AND KNOWLEDGE OF FIBROMYALGIA
Blotman F1,Thomas E1, Myon E2,Taieb C2
1CHU Montpellier, Montpellier, France; 2Health Economics & Quality
of Life Dept, Boulogne-Billancourt, France
OBJECTIVES: To assess the level of awareness and knowledge
of ﬁbromyalgia among General Practitioners (GP) and Rheuma-
tologists (R). METHODS: A questionnaire was sent to all prac-
ticing R and 10,000 French GP randomly selected. RESULTS: A
total of 1016 GP and 418 R (response rate: 10.2% and 16.7%
respectively) returned the completed questionnaire. A random
selection of 200 GP’s and 200 R responses were analysed.
Respectively for GP and R, FMS is an illness for 33% and 25%,
a syndrome for 64% and 72% and does not exist for 3% and
3%. FMS represents for GP and R respectively 1% of their con-
sultation for 74% and 33%; 2 to 5% for 24% and 64% and 10
to 20% for 1% and 3%. GP and R respectively recognized as
being 1 of the principal syndromes of Fibromyalgia (in % of
responders): diffuse pain for 83 and 92, digestive problems for
22 and 31, radiological anomaly for 6 and 1, troubled sleep for
57 and 87, lack of concentration and memory loss for 36 and
43, articular swelling for 15 and 6, muscular weakness for 76
and 45, a feeling of depression/anxiety/sadness for 78 and 82,
excessive tiredness for 90 and 93 and palpitations for 15 and 19.
CONCLUSIONS: The comparison between Rheumatologists
and General Practitioners reveals some signiﬁcant differences,
especially regarding the deﬁnition of FMS, which is considered
as an illness by 25% and 33% of the practitioners respectively.
Signiﬁcant differences also appear in their appreciation of the
associated symptoms (the frequency of articular swelling and
radiological anomalies in particular).
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FIBROMYALGIA SYNDROM: A FRENCH EPIDEMIOLOGICAL
SURVEY
Myon E,Taieb C
Health Economics & Quality of Life Dept, Boulogne-Billancourt,
France
OBJECTIVES: To estimate the prevalence of possible ﬁbromyal-
gia syndrome (FMS) among non-institutionalised French adults.
METHODS: The LFES-SQ (London Fibromyalgia Epidemiology
Study—Screening Questionnaire) were administered to 1018
individuals (>15 y.o.) representative of the French population
(IPSOS using quota method). The LFES-SQ questionnaire allows
to screen patients who might have FMS or a possible FMS; sub-
jects are screened positive if they answered yes to all the ques-
tions. RESULTS: From positive subjects to have the accurate
number of possible FMS patients (+) the following multiplica-
tion factors need to be used: multiplication factors of possible
FM patients V number of (+) = Estimated Total FM cases in
London/Number of Patients (+) in the London survey (i.e. 0.568
for the total population; 0.628 for women and 0.356 for men).
On our 1018 subjects (529 women, 489 men), 133 were screened
positive (80 women, 53 men). Therefore, using the multiplica-
tion factors we obtained 75.54 estimated FM cases (50.24
women, 18.87 men) i.e. an estimated prevalence of possible FM
in France of 7.42%, 9.5% of women and 3.86% of men. CON-
CLUSIONS: Those data are higher than the ones obtained in the
White study nor in the published prevalence of FMS in the lit-
erature, but they assess an estimated prevalence of possible FMS
(without validating the diagnosis with a rheumatologist). Next
step will be to calculate European multiplication factors and to
generalise this survey in Europe.
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SURVEY OF GLOBAL FIBROMYALGIA MANAGEMENT BY
FRENCH GENERAL PRACTITIONERS
Thomas E1, Blotman F1, Myon E2,Taieb C2
1CHU Montpellier, Montpellier, France; 2Health Economics & Quality
of Life Dept, Boulogne-Billancourt, France
OBJECTIVES: To describe the management by French General
Practitioners (GP) of patients suffering from ﬁbromyalgia (FMS).
METHODS: A questionnaire was sent to 10,000 French GP ran-
domly selected. RESULTS: First analysis of a random selection
of 200 responses on the 1016 questionnaires received (response
rate: 10.2%) showed that 34% are male with an average age of
47 years. A total of 73.5% of them have patients suffering from
FMS in their care: 34% have 5 or more patients, 6% have 10 or
more. Each GP has an average of 6.1 FMS patients and 88%
prescribe a fundamental treatment to their FMS patients: 77%
declare prescribing analgesics (A), 42% tricyclic antidepressants
(TCA), 55% serotoninergic antidepressants (SA), 23% hyp-
notics/sedatives (H/S), 21% homeopathic treatments (H) and 6%
morphine derived treatments(MD). A total of 82% prescribe
treatments for the symptomatic pain relief of their FMS patients:
66% prescribe A, 16% TCA, 15% SA, 34% H/S, 18% H and
9% MD. Ninety percent (90%) of GP’s recommend “alterna-
tive” treatment: 42% acupuncture; 3% chiropractic treatment;
9% hypnotherapy; 31% spas; 33% osteopathy and 74% relax-
ation techniques. For 85% of them physical exercise is part of
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the care: 78% recommend swimming; 68% regular walks; 55%
yoga; 27% stretching and 23% bicycling. CONCLUSIONS:
FMS is a frequently diagnosed illness in general medicine (6 FMS
patients/GP). The difﬁculties in treating the illness seem evident
as shown by the multiple therapeutic choices. We may note the





RELATIONSHIPS BETWEEN AGE, NUMBER OF
PRESCRIPTIONS,AND CO-MORBIDITIES AMONG VA
PATIENTS
Raisch DW, Harris CL, Netravali S, Campbell H
VA Cooperative Studies Program, Albuquerque, NM, USA
OBJECTIVE: To determine the relationship between the Charl-
son co-morbidity index and age and annual number of pre-
scriptions dispensed among a sample of Veterans Affairs 
(VA) patients receiving nonsteroidal anti-inﬂammatory agents
(NSAIDs). METHODS: NSAID patients treated at three VA
medical centers were identiﬁed from a previous study. Prescrip-
tion records, demographics, and International Classiﬁcation of
Disease-9 (ICD-9) diagnoses were obtained from the VA elec-
tronic databases. The comorbidity index for each patient was
determined by applying appropriate weights to ICD-9 diagnoses
and summing the weights for each patient. We applied stepwise
regression with co-morbidity index as the dependent variable
and age and number of prescriptions as independent variables.
We used VA-1 as the pilot study, to determine if a relationship
existed between the variables. We performed the same analyses
using the additional two medical centers to validate the rela-
tionship. RESULTS: There were 17,893 patients included in the
study, 7322 at VA-1, 6094 at VA-2, and 4447 at VA-3. Mean
ages ± standard deviations (SD) were 59.5 ± 13.3, 58.4 ± 13.0,
and 62.5 ± 13.1, respectively. Mean annual numbers of pre-
scriptions (±SD) were 33.6 ± 31.7, 31.8 ± 29.9, and 47.9 ± 39.5,
respectively. Mean comorbidity weights (±SD) were 2.1 ± 2.4,
1.5 ± 2.1, and 1.6 ± 1.9, respectively (p < 0.001). Stepwise regres-
sion results, with comorbidity as the dependent variable, were
signiﬁcant (p < 0.001) for age and number of prescriptions and
explained 20.2%, 16.7%, and 14.4% of the variance. When data
were combined and VA medical center was included, the model
explained 18.8% of the variance (p < 0.001 for medical center,
age and number of prescriptions). The adjusted mean comor-
bidity weights by VA medical center were 2.2 (standard error
(SE) = 0.023), 1.6 (SE = 0.25) and 1.3 (SE = 0.30) respectively.
CONCLUSION: Among VA NSAID patients, the annual
number of prescriptions, medical center, and age are strongly
related to the Charlson co-morbidity index.
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CROSS-VALIDATION OF A NEW QUESTIONNAIRE DESIGNED
TO PREDICT FUTURE RISK OF NSAID-INDUCED
GASTROINTESTINAL EVENTS
Livengood K,Ambegaonkar A, Craig T
Pﬁzer Inc, New York, NY, USA
OBJECTIVES: The objective of this study is to cross-validate a
new questionnaire designed to predict the future risk of NSAID-
induced gastrointestinal events against a standard questionnaire,
the GI SCORE survey. METHODS: Four-hundred consenting,
consecutive patients from a rheumatology clinic in the mid-
western United States were administered both questionnaires.
The questionnaires were not administered in any particular
order. The new questionnaire contains questions that are similar
to ﬁve of six questions found in GI SCORE, in addition to ﬁve
questions not found in GI SCORE. The completed GI SCORE
questionnaires were scored and the associated risk levels were
determined. Feasible generalized least squares (FGLS) and multi-
nomial logistic (MNL) regression were used to map the ques-
tions from the new questionnaire onto the scores and two
different groups of risk levels, respectively, determined from GI
SCORE. Based on the results of the FGLS analysis, a scoring
scheme was created for the new questionnaire, allowing the pre-
diction of risk levels similar to GI SCORE. Risk levels generated
from both FGLS and MNL were compared to those predicted
by GI SCORE. RESULTS: For FGLS, the new questionnaire pre-
dicted risk levels that matched those predicted by GI SCORE
with 83% accuracy. When the original 4 risk levels predicted by
GI SCORE were collapsed into 3 risk levels, with the 2 most
severe risk levels becoming a single risk level, the predictions
from the new questionnaire were 89% accurate. For MNL, the
new questionnaire was 76% and 87% accurate for four and
three risk levels, respectively. CONCLUSIONS: The new ques-
tionnaire appears to be reasonably accurate in predicting the
same risk as those predicted by a standard survey. FGLS is
slightly more accurate than MNL in predicting risk for both
groups of risk considered.
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COST-UTILITY OUTCOMES SIMULATION MODEL FOR
OSTEOARTHRITIS (OA) AND RHEUMATOID ARTHRITIS (RA)
PATIENTS (COSMO): DEVELOPMENT AND VALIDATION OF A
PHARMACOECONOMIC MODEL
Niculescu L1, Lising AW2, Neumann PJ3
1Pﬁzer Inc, New York, NY, USA; 2Dymaxium Inc,Toronto, ON, Canada;
3Harvard School of Public Health, Boston, MA, USA
OBJECTIVE: To construct a ﬂexible and transparent pharma-
coeconomic model to assess the value of COX-2 selective
inhibitors (COX-2s) in the treatment of arthritis. METHODS:
Literature searches and interviews with Health Care practition-
ers were conducted to identify critical issues for model con-
struction. Model assumptions and parameters estimates for the
new COSMO model were made based on these efforts. Conver-
gent validity was assessed by comparing COSMO model outputs
to results obtained using previously published models, when
similar inputs were used in each model. RESULTS: Because
arthritis patients often switch medications, the COSMO model
simulates treatment strategies, rather than individual drugs.
COSMO allows users to compare strategies under which patients
start on an NSAID or COX-2 and switch medications twice. It
was structured as a one-month cycle Markov model with the fol-
lowing disease states: GI discomfort, loss of efﬁcacy, complicated
ulcer, uncomplicated ulcer, CV event, no events, and death.
Inputs allowed for different levels of complexity to address the
difﬁculty in obtaining data sources in different countries. Multi-
ple clinical (number of deaths, GI discomfort, ulcers, uncon-
trolled arthritis) and economic (drug costs, costs of managing GI
and CV events, total costs) outputs were included. Monte Carlo
simulations, acceptability curves, cost-effectiveness planes and
extensive univariate and multi-variate sensitivity analysis can be
performed with any input. For base case analyses, we assume a
3rd party payer perspective. In the validation exercise, we
applied inputs from a published model (Maetzel et al., 2003),
and obtained similar results (7% variation) and similar trends 
in sensitivity analyses, suggesting strong convergent validity.
CONCLUSIONS: COSMO is a pharmacoeconomic model 
that assesses the value of different treatment strategies for
